Abstract:Background: Single-cell technologies provide invaluable insights into disease biology and drug development by revealing complex interactions among different cell types within patients. However, harnessing the potential of publicly available single-cell data remains challenging due to the lack of integrated data across diverse single cell platforms. Methods: To maximize the potential of single cell insights, we have created an AI/ML powered curation and data integration process within our Drug Intelligence Science (DIS®) platform. This automated process integrates single cell transcriptomic data from publicly available sources with our in-house generated datasets from ex vivo translational efforts and clinical programs. Relevant public datasets are identified and retrieved using an automated Python-based GEO dataset crawler tool, and standardized metadata are curated. A reference atlas of 31 immune and 4 non-immune cell types is generated from the database and is used to consistently label cells across datasets. Additionally, cell-level gene expression integration and normalization across datasets is achieved using generative modeling techniques. To facilitate multiuser visualization and interrogation of the curated and integrated datasets, we have developed Cellect, a customized version of CellxGene Gateway. Results: The current single-cell database comprises 15 million cells analyzed in >5,000 samples collected from >2,500 patients across 160 curated unique human studies, spanning oncology (56%), autoimmune disease (AID, 21%), and viral infection (15%), with the remaining being from reference healthy tissues (8%). We focused dataset curation on indications of interest for our internal clinical development efforts. Uniquely, data from approximately 300 patients who received standard of care (SOC) treatment including immune checkpoint inhibitor (IO) therapy were integrated to delineate mechanisms of drug response and resistance. The post-SOC resource was used to identify (1) treatment settings where these mechanisms are enriched and (2) markers co-expressed with targets of interest (e.g., PD1, CTLA4, OX40, TNFR2, etc.) in specific cell populations to inform combination strategies. Conclusions: We have presented an AI/ML guided approach to address the key challenge of integrating single-cell data across platforms and demonstrated that relevant disease biology is retained upon integration. We outline a path for deploying this solution at scale for bench and computational scientists to guide target as well as indication selection, as was done for our ongoing clinical programs, including our first-in-class TNFR2 agonist (HFB200301, NCT05238883) and second-generation OX40 agonist (HFB301001, NCT05229601). Citation Format: Jack Russella-Pollard, Joshua Whitener, Jordan Byck, Monika Manne, Hani Alostaz, Marianna Elia, Kamil Krukowski, Gabrielle Wong, Francisco Adrian, Liang Schweizer, Robert H. Andtbacka, Christos Hatzis. Integrating public single-cell transcriptomics and patient profiles to guide clinical development [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6202.

Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq data

Abstract A136: Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles

scPharm: identifying pharmacological subpopulations of single cells for precision medicine in cancers

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

Integration of pan-cancer cell line and single-cell transcriptomic profiles enables inference of therapeutic vulnerabilities in heterogeneous tumors

Single-Cell Multimodal Analytical Approach by Integrating Raman Optical Tweezers and RNA Sequencing

DrugReSC: targeting disease-critical cell subpopulations with single-cell transcriptomic data for drug repurposing in cancer

A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response

Drug combination prediction for cancer treatment using disease-specific drug response profiles and single-cell transcriptional signatures

Abstract 1906: Single cell precision oncology: A proof of principle

Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones

Deconvolution of cell type-specific drug responses in human tumor tissue with single-cell RNA-seq

Profiling the Non-genetic Origins of Cancer Drug Resistance with a Single-Cell Functional Genomics Approach Using Predictive Cell Dynamics

Using Single‐cell Multiple Omics Approaches to Resolve Tumor Heterogeneity

A single cell RNAseq benchmark experiment embedding "controlled" cancer heterogeneity

A Bayesian framework to study tumor subclone-specific expression by combining bulk DNA and single-cell RNA sequencing data

The Prospects of Tumor Chemosensitivity Testing at the Single-Cell Level.

Abstract 6202: Integrating public single-cell transcriptomics and patient profiles to guide clinical development

Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data

Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level